Immutep announces publication of TACTI-002 and TACTI-003 abstracts at ASCO 2022

Immutep announces publication of TACTI-002 and TACTI-003 abstracts at ASCO 2022

• Efti in combination with pembrolizumab continues to show favourable antitumor activity in first line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022
• Improved Overall Response Rate (ORR) of 37.3 percent (intent to treat, 28/75 patients) as assessed by local read based on 75 patients and compared to 36.1 percent at ASCO 2021
• Responses observed in all PD-L1 subgroups with 32 percent ORR in patients with no or low PD-L1 (TPS less than 50 percent)
• Improved Disease Control Rate of 73.3 percent (55/75) compared to 66.7 percent at ASCO 2021
• Combination of efti plus pembrolizumab continues to be safe and well tolerated
• Updated data from all 114 patients to be presented in an Oral Presentation on 3 June 2022

Sydney, Australia, May 27, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from Part A of the Phase II TACTI-002 trial in first line NSCLC has been published today in an abstract at the American Society of Clinical Oncology's (ASCO) 2022 Annual Meeting.

Data from the trial will be presented in an Oral Presentation on 3 June 2022. Importantly, while the abstract contains data from the first 75 patients with a data cut off of January 2022, the Oral Presentation will present data from all 114 patients with a more recent data cut off and will be the subject of a further announcement from the Company.

Immutep also announces the publication of an abstract for the design of the ongoing Phase IIb TACTI-003 trial that will be presented as a Trial-in-Progress Poster Presentation at ASCO 2022.

The respective abstracts are available via the links below and www.immutep.com. Similarly, the presentations will be available at the times indicated below on ASCO.org and subsequently made available on Immutep’s website. 

TACTI-002 Abstract

Title: A Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1 unselected population

Abstract link: https://tinyurl.com/y5ehrvkh

Oral presentation date:Friday 3 June 2022 at 1:00pm, US Central Daylight Time (CDT)

TACTI-003 Abstract

Title: TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous-cell carcinoma

Abstract link: https://tinyurl.com/2u3ax76t

Poster date: Monday 6 June 2022 at 1:15pm US CDT